Rationality for the use of essential phospholipids in the treatment of NAFLD


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Analysis of current international and domestic recommendations allows to conclude that the leading non-medicinal methods for treating non-alcoholic fatty liver disease include the use of a low-calorie diet with a sufficient content of polyunsaturated fats and graduated exercise to reduce body weight. Among the drugs, leading positions belong to insulin sensitizers, essential phospholipids (Essentiale Forte N) and antioxidants (vitamin E).

Full Text

Restricted Access

About the authors

V. V Tsukanov

Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences"; “Scientific Research Institute of Medical Problems of the North “

Email: gastro@impn.ru
MD, Prof., Head of the Clinical Department of the Pathology of the Digestive System in Adults and Children

A. V Vasyutin

Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences"; “Scientific Research Institute of Medical Problems of the North “

Yu. L Tonkikh

Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences"; “Scientific Research Institute of Medical Problems of the North “

References

  1. Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018;15(1):11-20.
  2. Younossi Z.M., Reyes M.J., Mishra A., Mehta R., Henry L. Systematic review with metaanalysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment. Pharmacol. Ther. 2014;39(1):3-14.
  3. Wong R.J., Aguilar M., Cheung R., Perumpail R.B., Harrison S.A., Younossi Z.M., Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148(3):547-55.
  4. Townsend S.A., Newsome P.N. Review article: new treatments in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2017;46(5):494-507.
  5. Маев И.В., Цуканов В.В., Лукичева Э.В., Самсонов А.А., Васютин А.В., Никушкина И.Н. Распространенность, патогенез и принципы лечения неалкогольной жировой болезни печени. Фарматека. 2011;12:12-5.
  6. Dowman J.K., Tomlinson J.W., Newsome P.N. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2011;33(5):525-40.
  7. Rinella M.E., Loomba R., Caldwell S.H., Kowdley K., Charlton M., Tetri B., Harrison S.A. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol. Hepatol. (N Y). 2014;10(4):219-27.
  8. Marchesini G., Day C.P., Dufour J.F., Canbay A., Nobili V, Ratziu V., Tilg H., Roden M., Gastaldelli A., Yki-Järvinen H., Schick F., Vettor R., Frühbeck G., Mathus-Vliegen L. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64(6):1388-402.
  9. Pearlman M., Loomba R. State of the art: treatment of nonalcoholic steatohepatitis. Curr. Opin. Gastroenterol. 2014;30(3):223-37.
  10. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Тихонов И.Н., Широкова Е.Н., Буеверов А.О., Драпкина О.М., Шульпекова Ю.О., Цуканов В.В., Маммаев С.Н., Маев И.В., Пальгова Л.К. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Росс. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 2:19-23.
  11. Jump D.B., Lytle K.A., Depner C.M., Tripathy S. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacol Ther. 2018;181:108-25.
  12. Puri R, Baillie R.A., Wiest M.M., Mirshahi F., Choudhury J., Cheung O., Sargeant C., Contos M.J., Sanyal A.J. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46(4):1081-90.
  13. Petit J.M., Guiu B., Duvillard L., Jooste V., Brindisi M.C., Athias A., Bouillet B., Habchi M., Cottet V., Gambert P., Hillon P., Cercueil J.P., Verges B. Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes. Clin. Nutr. 2012;31(4):520-25.
  14. Tripathy S., Lytle K.A., Stevens R.D., Bain J.R., Newgard C.B., Greenberg A.S., Huang L.S., Jump D.B. Fatty acid elongase-5 (Elovl5) regulates hepatic triglyceride catabolism in obese C57BL/6J mice. J. Lipid Res. 2014;55(7):1448-64.
  15. Anstee Q.M., Day C.P A lipid to treat nonalcoholic fatty liver disease - the dawn of «lipo-rehabilitation»?J. Hepatol. 2012;56(4):987-89.
  16. Li Y.H., Yang L.H., Sha K.H., Liu T.G., Zhang L.G., Liu X.X. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World J. Gastroenterol. 2015;21(22):7008-13.
  17. Argo C.K., Patrie J.T., Lackner C., Henry T.D., de Lange E.E., Weltman A.L., et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebocontrolled trial. J. Hepatol. 2015;62(1): 190-97.
  18. Qin Y., Zhou Y., Chen S.H., Zhao X.L., Ran L., Zeng X.L., Wu Y., Chen J.L., Kang C., Shu F.R., Zhang Q.Y., Mi M.T. Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. PLoS One. 2015;10(7):e0133496.
  19. Scorletti E., Bhatia L., McCormick K.G., Clough G.F., Nash K., Hodson L., Moyses H.E., Calder P.C., Byrne C.D. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology. 2014;60(4):1211-21.
  20. Nascimbeni F., Pais R., Bellentani S., Day C.P., Ratziu V., Loria P., Lonardo A. From NAFLD in clinical practice to answers from guidelines. J. Hepatol. 2013;59(4):859-71.
  21. Parker H.M., Johnson N.A., Burdon C.A., Cohn J.S., O'Connor H.T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol. 2012;56(4):944-51.
  22. He X.X., Wu X.L., Chen R.P, Chen C., Liu X.G., Wu B.J., Huang Z.M. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11(10):e0162368.
  23. Lu W., Li S., Li J., Wang J., Zhang R., Zhou Y., Yin Q., Zheng Y., Wang F., Xia Y., Chen K., Liu T., Lu J., Zhou Y., Guo C. Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Gastroenterol. Res. Pract. 2016;2016:1459790.
  24. Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., Harrison S.A., Brunt E.M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1): 328-57.
  25. Chitturi S., Wong V.W., Chan W.K., Wong G.L., Wong S.K., Sollano J., Ni Y.H., Liu C.J., Lin Y.C., Lesmana L.A., Kim S.U., Hashimoto E., Hamaguchi M., Goh K.L., Fan J., Duseja A., Dan Y.Y., Chawla Y., Farrell G., Chan H.L. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J. Gastroenterol. Hepatol. 2018;33(1):86-98.
  26. Gundermann K.J., Kuenker A., Kuntz E., Drozdzik M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011;63(3):643-59.
  27. Sas E., Grinevich V., Efimov O., et al. Beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study. J. Hepatol. 2013;58(Suppl. 1):S549.
  28. Dajani A.I., Abu Hammour A.M., Zakaria M.A., Al Jaberi M.R., Nounou M.A., Semrin A.I. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab. J. Gastroenterol. 2015;16(3-4): 99-104.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies